Nifty 50
- Adani Ports₹1,82485.70 (4.93%)
- TCS₹2,105-85.00 (-3.88%)
- Adani Enterprises₹3,02096.80 (3.31%)
- Tata Motors PV₹303.80-10.70 (-3.40%)
- Bharti Airtel₹1,893.3057.30 (3.12%)
- SBI Life Insurance ₹1,731-35.90 (-2.03%)
- HDFC Bank₹73118.00 (2.52%)
- Coal India₹409.90-8.10 (-1.94%)
- Bajaj Finance₹1,040.3025.30 (2.49%)
- Maruti Suzuki₹12,103-235.00 (-1.90%)
- Power Grid Corp₹270.306.55 (2.48%)
- NTPC₹323.65-5.95 (-1.81%)
- UltraTech Cement₹11,014250.00 (2.32%)
- Tata Consumer ₹996-17.70 (-1.75%)
- Apollo Hospitals₹8,944.50176.00 (2.01%)
- Sun Pharmaceutical₹1,837.30-30.00 (-1.61%)
- JSW Steel₹1,275.6022.20 (1.77%)
- Tech Mahindra₹1,537.10-23.90 (-1.53%)
- InterGlobe Aviation₹4,92075.00 (1.55%)
- ITC₹262.30-3.90 (-1.47%)
- Offerings
- Tools & Platforms
Tools & Calculators
- Open API
- Calculators
- SIP Calculator
- CAGR Calculator
- Compound Interest Calculator
- FD Calculator
- RD Calculator
- EPF Calculator
- Retirement Calculator
- HDFC SIP Calculator
- Mutual Fund Return Calculator
- Lumpsum Calculator
- Step Up SIP Calculator
- ETF SIP Calculator
- Brokerage Calculator
- Equity Margin Calculator
- SWP Calculator
- EMI Calculator
- MTF Calculator
- Margin Pledge Calculator
- Algo Strategy
- Markets
Stocks
F&O
Mutual Funds
- More
Godavari Biorefineries Stock Hits Upper Circuit After Company Gets European Patent for Anti-Cancer Molecule
Authored By Shishta Dutta | Last Modified: Oct 13, 2025 12:20 PM IST

Open Free Demat Account
Open Free Demat Account
Mumbai, July 4, 2025 – Godavari Biorefineries Ltd (NSE: GODAVARIB, BSE: 544279) surged 5% in early trade, hitting the upper circuit following the announcement of a European patent grant for a novel anti-cancer molecule. The company disclosed that the patent received is for a potent anti-cancer compound with proven efficacy against cancer cells and cancer stem cells.
The patent has been validated in Spain and the UK, as well as under EU provisions as a Unitary Patent, covering its Anti-Cancer Research Segment. The patent development enhances the company’s innovation credentials and positions it favorably in the global nutraceutical and biopharma ingredient space.
As of 12:06 PM on July 4, the stock was trading at ₹256.75, a 5.00% increase for the day.
Stock Movement
| Price Metrics (₹) | Value |
|---|---|
| Last Traded Price | 256.75 |
| % Change | +5.00% |
| Previous Close | 244.53 |
| Intraday High | 256.75 |
| Intraday Low | 256.50 |
| VWAP | 256.62 |
- Buy Quantity (Top Bid): 2,45,416 shares
- Traded Volume: 0.09 lakh shares
- Market Cap: ₹1,313.94 crore
- Free Float Market Cap: ₹404.64 crore
Key Regulatory Details
- Disclosure Regulation: SEBI LODR Reg. 30
- Adjusted P/E Ratio: 472.05
- Trading Status: Active
- Series: BE (Scrip PE > 50 for last 4 trailing quarters)
- Listing Date: 30-Oct-2024
Market Context
The stock’s strong upward momentum has placed it among the Top 10 gainers for the day, with no sell-side pressure visible in the order book. The script continues to trade in the BE (book entry) segment, which implies trading is settled on a delivery basis with a 100% margin.
Strategic Outlook
The patent grant marks a strategic breakthrough for Godavari Biorefineries in high-value biotech research, paving the way for monetisation through licensing or partnerships in the oncology domain. The anti-cancer molecule, validated across multiple European jurisdictions, significantly enhances the company’s growing innovation pipeline.
About the Company
Godavari Biorefineries Ltd, listed on both NSE and BSE, operates in the Diversified FMCG and bio-based chemical manufacturing sector. The company is part of the Somaiya Group and has a legacy in sustainable chemical production derived from renewable resources. It was listed in October 2024 under the NIFTY IPO index.
REF: https://nsearchives.nseindia.com/corporate/GODAVARIBIO_03072025205924_Intimation_to_SE.pdf
Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.
If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.
Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations
More Markets News
Open Free Demat Account
Open Free Demat Account





By signing up I certify terms, conditions & privacy policy

Join Us
Add as preferred source on Google













